Arnd Kaltofen-Ehmann

XO Life stands for ✅ a state-of-the-art platform solution for long-term Patient Insights from the real world ✅ real time information exchange between patients and pharma ✅ a all-in-one platform to be used across all treatments and indications We are a young and dynamic eHealth company setting a new standard patient data collection through scientifically based questionnaires across all treatments and medications. XO Life helps the pharmaceutical industry to better understand its patients. Our goal is to make digital treatment monitoring and patient feedback the gold standard in R&D, marketing and sales, while ensuring the highest data protection and security standards. ➡️ Join us in shaping the future of patient centered medical data collection and learn more at:

HighLife is a trans-catheter mitral valve replacement company committed to bringing the best minimally invasive technology to the patients.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

XO Life stands for ✅ a state-of-the-art platform solution for long-term Patient Insights from the real world ✅ real time information exchange between patients and pharma ✅ a all-in-one platform to be used across all treatments and indications We are a young and dynamic eHealth company setting a new standard patient data collection through scientifically based questionnaires across all treatments and medications. XO Life helps the pharmaceutical industry to better understand its patients. Our goal is to make digital treatment monitoring and patient feedback the gold standard in R&D, marketing and sales, while ensuring the highest data protection and security standards. ➡️ Join us in shaping the future of patient centered medical data collection and learn more at:

HighLife is a trans-catheter mitral valve replacement company committed to bringing the best minimally invasive technology to the patients.

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’ highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Europe, and China, Oculis’ goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

Healthcare & Technology Venture Capital since 2001. Vi Partners is the longest-established Swiss Venture Capital firm. For more than 20 years, Vi Partners has been supporting innovative Technology and Healthcare companies, investing over CHF 330m in 70 startups. Vi Partners-managed funds are backed by Switzerland’s most visible companies and institutions, including ETH Zurich, ABB, Buhler, Credit Suisse, Hilti, McKinsey, Nestlé, Schindler, Sulzer, Suva and ZKB as well as the European Investment Fund and many other institutional investors. Security Notice: Vi Partners does not solicit payments, or conduct business via private messaging apps. All legitimate engagement is initiated exclusively from @vipartners.ch email addresses.